In another series of NSCLC patients with leptomeningeal metastasis who had failed gefitinib treatment, all 6 patients with an EGFR mutation-derived clinical benefit with 3 PRs and 3 with SD (39). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.